Can IL-2 keep HIV patients healthier without antiretrovirals?
NCT ID NCT00120185
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether interleukin-2 (IL-2) can help maintain CD4 cell counts in people with HIV who have not yet started antiretroviral therapy. 130 participants with CD4 counts between 300 and 500 will receive IL-2 injections. The goal is to see if IL-2 can delay the need for standard HIV medications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Interleukin-2 (IL-2)
- What this could lead to
- If successful, this could show that IL-2 helps delay the need for antiretroviral therapy in early HIV infection.
- What could go wrong
- This is a small, early-phase trial with only 130 participants. IL-2 may not prevent CD4 decline, and side effects are possible. Results may not apply to all HIV patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Service des Maladies Infectieuses
Paris, 75010, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop anal lesions from becoming cancer?
- Can resilience defeat HIV stigma? a new study investigates
- Peer support may curb HIV stigma and stress in vietnamese gay men
- A pharmacist's touch: could structured medication reviews boost HIV treatment success?
- A new Fast-Track HIV care model aims to Re-Engage those lost to care
- Can a smartphone app curb HIV risk in south Korea's young gay men?